InterCure Ltd. (INCR.TA)
ILA 491.2
(1.93%)
ILA 491.2
(1.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -23.9 Million ILS | -27.8% |
| 2022 | 64.5 Million ILS | 71.64% |
| 2021 | 37.44 Million ILS | 1981.94% |
| 2020 | -34.52 Million ILS | 108.51% |
| 2019 | -21.2 Million ILS | -159.82% |
| 2018 | -10.12 Million ILS | -647.8% |
| 2017 | -1.14 Million ILS | -2.06% |
| 2016 | - ILS | 34.78% |
| 2015 | -1.63 Million ILS | 25.74% |
| 2014 | -3.76 Million ILS | -17.4% |
| 2013 | -1.88 Million ILS | 11.53% |
| 2012 | -2.09 Million ILS | -28.99% |
| 2011 | -1.64 Million ILS | 64.16% |
| 2010 | -4.59 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 7.2 Million ILS | 256.74% |
| 2024 Q2 | 7.2 Million ILS | 0.0% |
| 2023 Q4 | -4.59 Million ILS | 3.68% |
| 2023 FY | - ILS | -27.8% |
| 2023 Q1 | 10.65 Million ILS | 275.01% |
| 2023 Q2 | 6.55 Million ILS | -38.47% |
| 2023 Q3 | -4.77 Million ILS | -172.78% |
| 2022 Q3 | 16.39 Million ILS | -38.82% |
| 2022 Q4 | -6.08 Million ILS | -137.12% |
| 2022 FY | - ILS | 71.64% |
| 2022 Q1 | 22.39 Million ILS | 65.57% |
| 2022 Q2 | 26.8 Million ILS | 19.7% |
| 2021 Q2 | 9.51 Million ILS | 43.43% |
| 2021 Q4 | 13.52 Million ILS | 71.17% |
| 2021 FY | - ILS | 1981.94% |
| 2021 Q1 | 6.63 Million ILS | 21.9% |
| 2021 Q3 | 7.9 Million ILS | -16.99% |
| 2020 FY | - ILS | 108.51% |
| 2020 Q2 | -468 Thousand ILS | 93.67% |
| 2020 Q3 | 4.35 Million ILS | 1030.77% |
| 2020 Q1 | -7.39 Million ILS | -123.47% |
| 2020 Q4 | 5.44 Million ILS | 24.98% |
| 2019 Q3 | -14.02 Million ILS | 4.23% |
| 2019 Q1 | 10.93 Million ILS | 321.45% |
| 2019 Q2 | -14.64 Million ILS | -233.93% |
| 2019 FY | - ILS | -159.82% |
| 2019 Q4 | -3.31 Million ILS | 76.4% |
| 2018 Q4 | -4.93 Million ILS | 0.0% |
| 2018 Q2 | -124.5 Thousand ILS | 0.0% |
| 2018 FY | - ILS | -647.8% |
| 2018 Q1 | -124.5 Thousand ILS | 63.68% |
| 2018 Q3 | -4.93 Million ILS | -3865.86% |
| 2017 Q4 | -342.82 Thousand ILS | 0.0% |
| 2017 FY | - ILS | -2.06% |
| 2017 Q3 | -342.82 Thousand ILS | -51.2% |
| 2017 Q2 | -226.73 Thousand ILS | 3.69% |
| 2017 Q1 | -235.42 Thousand ILS | 48.53% |
| 2016 FY | - ILS | 34.78% |
| 2016 Q1 | -37.8 Thousand ILS | 96.08% |
| 2016 Q2 | -289.19 Thousand ILS | -664.95% |
| 2016 Q3 | -292.84 Thousand ILS | -1.26% |
| 2016 Q4 | -457.37 Thousand ILS | -56.18% |
| 2015 Q2 | 230.56 Thousand ILS | 223.72% |
| 2015 Q4 | -963.72 Thousand ILS | -160.93% |
| 2015 Q3 | -369.33 Thousand ILS | -260.19% |
| 2015 Q1 | 71.22 Thousand ILS | 153.59% |
| 2015 FY | - ILS | 25.74% |
| 2014 Q2 | -580.13 Thousand ILS | -20.93% |
| 2014 Q1 | -479.74 Thousand ILS | -139.91% |
| 2014 FY | - ILS | -17.4% |
| 2014 Q4 | -132.89 Thousand ILS | 68.92% |
| 2014 Q3 | -427.52 Thousand ILS | 26.31% |
| 2013 Q1 | -1.16 Million ILS | 81.12% |
| 2013 Q2 | -1.47 Million ILS | -26.54% |
| 2013 FY | - ILS | 11.53% |
| 2013 Q3 | -510.22 Thousand ILS | 65.29% |
| 2013 Q4 | 1.2 Million ILS | 335.62% |
| 2012 Q1 | -274.89 Thousand ILS | 0.0% |
| 2012 Q3 | 1.91 Million ILS | -19.93% |
| 2012 FY | - ILS | -28.99% |
| 2012 Q4 | -6.15 Million ILS | -421.54% |
| 2012 Q2 | 2.39 Million ILS | 969.75% |
| 2011 FY | - ILS | 64.16% |
| 2010 FY | - ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cannabotech LTD | -14.81 Million ILA | -61.377% |